Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan M Winter

Showing results (131-140 of 174) with videos related to

Pageof 18
Sort By:
Surgery|November 19, 2022
Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignanciesMohamedraed Elshami, Fasih Ali Ahmed, Jonathan J Hue, et al.
Surgery|November 29, 2021
A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problemsJonathan J Hue, Erryk S Katayama, Sarah C Markt, et al.
Annals of Surgery|April 25, 2006
Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosisJordan M Winter, John L Cameron, Keith D Lillemoe, et al.
Psycho-Oncology|April 26, 2022
Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancerNathaniel E Davis, Jonathan J Hue, Ravi K Kyasaram, et al.
Annals of Surgery|August 14, 2014
The HYSLAR trial: a prospective randomized controlled trial of the use of a restrictive fluid regimen with 3% hypertonic saline versus lactated Ringers in patients undergoing pancreaticoduodenectomyHarish Lavu, Naomi M Sell, Timothy I Carter, et al.
Annals of Surgery|November 29, 2016
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical TrialTalar Tatarian, Wei Jiang, Benjamin E Leiby, et al.
Surgical Oncology|June 21, 2020
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experienceCinthya Y Lowder, Teena Dhir, Austin B Goetz, et al.
Molecular Cancer Research : MCR|April 8, 2016
HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer CellsCarmella Romeo, Matthew C Weber, Mahsa Zarei, et al.
Annals of Surgery|April 13, 2023
Discordance Between Conventional and Detailed Lymph Node Analysis in Resected, Node-negative Pancreatic or Ampullary Adenocarcinomas and Association With Adverse Survival Outcomes: A Single-institution AnalysisMohamedraed Elshami, Alwalid K Ammoun, Wadad S Mneimneh, et al.
Cancer Research|February 19, 2014
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cellsShruti Lal, Richard A Burkhart, Neil Beeharry, et al.
Pageof 18

Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
Surgery|November 19, 2022
Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignanciesMohamedraed Elshami, Fasih Ali Ahmed, Jonathan J Hue, et al.
Surgery|November 29, 2021
A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problemsJonathan J Hue, Erryk S Katayama, Sarah C Markt, et al.
Annals of Surgery|April 25, 2006
Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosisJordan M Winter, John L Cameron, Keith D Lillemoe, et al.
Psycho-Oncology|April 26, 2022
Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancerNathaniel E Davis, Jonathan J Hue, Ravi K Kyasaram, et al.
Annals of Surgery|August 14, 2014
The HYSLAR trial: a prospective randomized controlled trial of the use of a restrictive fluid regimen with 3% hypertonic saline versus lactated Ringers in patients undergoing pancreaticoduodenectomyHarish Lavu, Naomi M Sell, Timothy I Carter, et al.
Annals of Surgery|November 29, 2016
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical TrialTalar Tatarian, Wei Jiang, Benjamin E Leiby, et al.
Surgical Oncology|June 21, 2020
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experienceCinthya Y Lowder, Teena Dhir, Austin B Goetz, et al.
Molecular Cancer Research : MCR|April 8, 2016
HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer CellsCarmella Romeo, Matthew C Weber, Mahsa Zarei, et al.
Annals of Surgery|April 13, 2023
Discordance Between Conventional and Detailed Lymph Node Analysis in Resected, Node-negative Pancreatic or Ampullary Adenocarcinomas and Association With Adverse Survival Outcomes: A Single-institution AnalysisMohamedraed Elshami, Alwalid K Ammoun, Wadad S Mneimneh, et al.
Cancer Research|February 19, 2014
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cellsShruti Lal, Richard A Burkhart, Neil Beeharry, et al.
Pageof 18